Sign inJoin waitlistJoin the waitlist

Michael Bookman

Director of Gynecologic Oncology Therapeutics · Kaiser Permanente

Credentials: · · · · · ·

History

Gynecologic Cancer InterGroup
2024–Present
Kaiser Permanente San Francisco
Present

National Cancer Institute
1983–1985
Internal Medicine
Beth Israel Deaconess Medical Center
1980–1983
Harvard Medical School
1976–1980

Research

Incorporation of bevacizumab in the primary treatment of ovarian cancer
New England Journal of Medicine · 2011 · 1,905 citations
The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck
Cell · 1988 · 1,499 citations
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Nature reviews. Cancer · 2015 · 971 citations

RO
Robert Ozols
20 papers
Kathleen Moore
19 papers
RB
Robert Burger
16 papers
RC
Robert Coleman
16 papers
CA
Carol Aghajanian
14 papers
Gini Fleming
13 papers
Thomas Krivak
13 papers
David Mutch
12 papers
Deborah Armstrong
12 papers
Krishnansu Tewari
12 papers
Larry Copeland
12 papers
Robert Mannel
10 papers

Grants

FCCC-PENN SPORE in Ovarian Cancer
National Cancer Institute · P50
Project lead · $2.4M · Research Inst of Fox Chase Can Ctr
1999–2015
Comprehensive Cancer Center Program at Fox Chase
National Cancer Institute · P30
Project lead · $784.9K · Research Inst of Fox Chase Can Ctr
2001–2003

Clinical trials

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Principal investigator · Completed · Phase 3
Gynecologic Oncology Group
2001–2013
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Study chair · Completed · Phase 1
Gynecologic Oncology Group
2000
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
Study chair · Unknown · Phase 2
AltaRex
1998